Pathfinder Cell Therapy (PFND) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access PFND Annual Balance Sheets →
Balance sheet performance over multiple periods helps investors evaluate the financial resilience of Pathfinder Cell Therapy.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2015)
(Jun 30 2015) (Mar 31 2015) (Dec 31 2014) (Sep 30 2014)
Assets
Cash & cash equivalent0.00
Cash & Short-term Investments0.00
Prepaid Expense, Current AS0.01
Total Current Assets0.01
Intangible Assets0.03
Total Assets0.04
Liabilities
Accounts Payable, Current AC0.33
Accrued Liabilities, Current AC1.03
Convertible Notes Payable, Current NO5.17
Other Liabilities, Current0.24
Total Current Liabilities6.77
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Total Liabilities6.77
Stockholders' Equity
Common Stock Value0.67
Additional Paid In Capital Common Stock11.83
Retained Earnings / Accumulated Deficit-19.23
Other Equity0.00
Common Stockholder's Equity-6.73
Total Stockholder's Equity-6.73
Liabilities & Stockholder's Equity0.04
4 historic quarters locked

Sign in to unlock the full Pathfinder Cell Therapy balance sheet history.

About PFND Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.